Tags

Type your tag names separated by a space and hit enter

Use of dronabinol for cannabis dependence: two case reports and review.
Am J Addict. 2008 Mar-Apr; 17(2):161-4.AJ

Abstract

Marijuana is the most commonly used illicit drug in the United States and throughout the world. Despite this, the number of laboratory studies that have assessed pharmacologic agents to target cannabis withdrawal symptoms or reduce the reinforcing effects of marijuana has been modest. Unlike alcohol, cocaine, opiates, or nicotine, there has been a minimal number of clinical pharmacologic treatment trials that have targeted marijuana use. Based on recent laboratory studies, dronabinol (delta-9-tetrahydrocannabinol) has been shown to reduce cannabis withdrawal symptoms and the subjective effects of marijuana. Given that agonist agents have been found to be effective for opiate and nicotine dependence, the clinical utility of dronabinol for cannabis dependence is a reasonable approach. Two case reports using dronabinol are presented. The potential benefit, as well as questions that arise from the use of this medication in cannabis-abusing populations, is presented. Also, future areas of research that might be explored are discussed.

Authors+Show Affiliations

Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA. frl2@columbia.eduNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Review

Language

eng

PubMed ID

18393061

Citation

Levin, Frances R., and Herbert D. Kleber. "Use of Dronabinol for Cannabis Dependence: Two Case Reports and Review." The American Journal On Addictions, vol. 17, no. 2, 2008, pp. 161-4.
Levin FR, Kleber HD. Use of dronabinol for cannabis dependence: two case reports and review. Am J Addict. 2008;17(2):161-4.
Levin, F. R., & Kleber, H. D. (2008). Use of dronabinol for cannabis dependence: two case reports and review. The American Journal On Addictions, 17(2), 161-4. https://doi.org/10.1080/10550490701861177
Levin FR, Kleber HD. Use of Dronabinol for Cannabis Dependence: Two Case Reports and Review. Am J Addict. 2008 Mar-Apr;17(2):161-4. PubMed PMID: 18393061.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of dronabinol for cannabis dependence: two case reports and review. AU - Levin,Frances R, AU - Kleber,Herbert D, PY - 2008/4/9/pubmed PY - 2008/7/9/medline PY - 2008/4/9/entrez SP - 161 EP - 4 JF - The American journal on addictions JO - Am J Addict VL - 17 IS - 2 N2 - Marijuana is the most commonly used illicit drug in the United States and throughout the world. Despite this, the number of laboratory studies that have assessed pharmacologic agents to target cannabis withdrawal symptoms or reduce the reinforcing effects of marijuana has been modest. Unlike alcohol, cocaine, opiates, or nicotine, there has been a minimal number of clinical pharmacologic treatment trials that have targeted marijuana use. Based on recent laboratory studies, dronabinol (delta-9-tetrahydrocannabinol) has been shown to reduce cannabis withdrawal symptoms and the subjective effects of marijuana. Given that agonist agents have been found to be effective for opiate and nicotine dependence, the clinical utility of dronabinol for cannabis dependence is a reasonable approach. Two case reports using dronabinol are presented. The potential benefit, as well as questions that arise from the use of this medication in cannabis-abusing populations, is presented. Also, future areas of research that might be explored are discussed. SN - 1521-0391 UR - https://www.unboundmedicine.com/medline/citation/18393061/Use_of_dronabinol_for_cannabis_dependence:_two_case_reports_and_review_ L2 - https://doi.org/10.1080/10550490701861177 DB - PRIME DP - Unbound Medicine ER -